Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms

Since the emergence of a novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported from Wuhan, China, neither a specific vaccine nor an antiviral drug against SARS-CoV-2 has become available. However, a combination of two HIV-1 protease inhibitors, lopinavir and ritonavir, has been found to be effective against SARS-CoV, and both drugs could bind well to the SARS-CoV 3C-like protease (SARS-CoV 3CLpro). In this work, molecular complexation between each inhibitor and SARS-CoV-2 3CLpro was studied using all-atom molecular dynamics simulations, free energy calculations, and pair interaction energy analyses based on MM/PB(GB)SA and FMO-MP2/PCM/6-31G* methods. Both anti-HIV drugs interacted well with the residues at the active site of SARS-CoV-2 3CLpro. Ritonavir showed a somewhat higher number atomic contacts, a somewhat higher binding efficiency, and a somewhat higher number of key binding residues compared to lopinavir, which correspond with the slightly lower water accessibility at the 3CLpro active site. In addition, only ritonavir could interact with the oxyanion hole residues N142 and G143 via the formation of two hydrogen bonds. The interactions in terms of electrostatics, dispersion, and charge transfer played an important role in the drug binding. The obtained results demonstrated how repurposed anti-HIV drugs could be used to combat COVID-19.

[1]  Holger Gohlke,et al.  MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.

[2]  D. Hamer.  Faculty Opinions recommendation of Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[3]  Songmi Kim,et al.  Application of the fragment molecular orbital method to discover novel natural products for prion disease , 2018, Scientific Reports.

[4]  R. Hilgenfeld,et al.  A Structural View of the Inactivation of the SARS Coronavirus Main Proteinase by Benzotriazole Esters , 2008, Chemistry & Biology.

[5]  Guangdi Li,et al.  Approved Antiviral Drugs over the Past 50 Years , 2016, Clinical Microbiology Reviews.

[6]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[7]  Martin W. Feyereisen,et al.  Use of approximate integrals in ab initio theory. An application in MP2 energy calculations , 1993 .

[8]  Harwood Fisher.  The Structural View , 2020 .

[9]  Qinggang Zhang,et al.  Effect of electrostatic polarization and bridging water on CDK2-ligand binding affinities calculated using a highly efficient interaction entropy method. , 2017, Physical chemistry chemical physics : PCCP.

[10]  Z. Rao,et al.  Drug design targeting the main protease, the Achilles' heel of coronaviruses. , 2006, Current pharmaceutical design.

[11]  Kazuo Kitaura,et al.  Pair interaction energy decomposition analysis , 2007, J. Comput. Chem..

[12]  Christian Drosten,et al.  Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group , 2013, Journal of Virology.

[13]  T. Rungrotmongkol,et al.  Butoxy Mansonone G Inhibits STAT3 and Akt Signaling Pathways in Non-Small Cell Lung Cancers: Combined Experimental and Theoretical Investigations , 2019, Cancers.

[14]  Zhènglì Shí,et al.  The crystal structure of COVID-19 main protease in complex with an inhibitor N3 , 2020 .

[15]  Xiu-Jie Wang,et al.  Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines , 2020, Journal of Genetics and Genomics.

[16]  R. Zeldin,et al.  Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. , 2003, The Journal of antimicrobial chemotherapy.

[17]  V. Lee,et al.  Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors , 2008, Journal of Theoretical Biology.

[18]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[19]  T. Langer,et al.  Multiple Virtual Screening Strategies for the Discovery of Novel Compounds Active Against Dengue Virus: A Hit Identification Study , 2019 .

[20]  T. Rungrotmongkol,et al.  Atomistic mechanisms underlying the activation of the G protein-coupled sweet receptor heterodimer by sugar alcohol recognition , 2019, Scientific Reports.

[21]  Thanyada Rungrotmongkol,et al.  Key Binding and Susceptibility of NS3/4A Serine Protease Inhibitors against Hepatitis C Virus , 2014, J. Chem. Inf. Model..

[22]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[23]  Krishna Bisetty,et al.  Structural insights into Rab21 GTPase activation mechanism by molecular dynamics simulations , 2018 .

[24]  Ramu Anandakrishnan,et al.  H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations , 2012, Nucleic Acids Res..

[25]  G. Gao,et al.  Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses , 2016, Trends in Microbiology.

[26]  Alimuddin Zumla,et al.  Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.

[27]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[28]  T. Schirmeister,et al.  Cysteine Proteases and Their Inhibitors. , 1997, Chemical reviews.

[29]  Z. Memish,et al.  Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial , 2018, Trials.

[30]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[31]  Yuguang Mu,et al.  Dynamically-Driven Inactivation of the Catalytic Machinery of the SARS 3C-Like Protease by the N214A Mutation on the Extra Domain , 2011, PLoS Comput. Biol..

[32]  T. Rungrotmongkol,et al.  Binding recognition of substrates in NS2B/NS3 serine protease of Zika virus revealed by molecular dynamics simulations. , 2019, Journal of molecular graphics & modelling.

[33]  Hualiang Jiang,et al.  Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.

[34]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[35]  Y. Guan,et al.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.

[36]  K. Kousoulas,et al.  Biological and genetic characterization of a hemagglutinating coronavirus isolated from a diarrhoeic child , 1994, Journal of medical virology.

[37]  C. Hicks,et al.  Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection , 2005, Expert opinion on pharmacotherapy.

[38]  Qing‐Yu He,et al.  Two zinc-binding domains in the transporter AdcA from Streptococcus pyogenes facilitate high-affinity binding and fast transport of zinc , 2018, The Journal of Biological Chemistry.

[39]  T. Rungrotmongkol,et al.  Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation. , 2019, Journal of molecular graphics & modelling.

[40]  Mitchell A. Avery,et al.  Inhibitors of SARS-3CLpro: Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation Studies , 2011, J. Chem. Inf. Model..

[41]  Qinggang Zhang,et al.  Revealing Origin of Decrease in Potency of Darunavir and Amprenavir against HIV-2 relative to HIV-1 Protease by Molecular Dynamics Simulations , 2014, Scientific Reports.

[42]  A. Niknejad.  Application of Singular Value Decomposition , 2005 .

[43]  Rolf Hilgenfeld,et al.  Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.

[44]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[45]  R. Baric,et al.  Coronavirus Genome Structure and Replication , 2005, Current topics in microbiology and immunology.

[46]  John J. Irwin,et al.  ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..

[47]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[48]  G. Panayiotakopoulos,et al.  Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event , 2020, bioRxiv.

[49]  Yuto Komeiji,et al.  Fragment molecular orbital method: analytical energy gradients , 2001 .

[50]  Kaori Fukuzawa,et al.  Application of singular value decomposition to the inter-fragment interaction energy analysis for ligand screening , 2018 .

[51]  Marian Anghel,et al.  Synchronization of trajectories in canonical molecular-dynamics simulations: observation, explanation, and exploitation. , 2004, The Journal of chemical physics.

[52]  W. Wooster,et al.  Crystal structure of , 2005 .

[53]  R. Hilgenfeld,et al.  Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors , 2020, Science.

[54]  Daniel R Roe,et al.  PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. , 2013, Journal of chemical theory and computation.

[55]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[56]  H. Field,et al.  Epidemiologic Clues to SARS Origin in China , 2004, Emerging infectious diseases.

[57]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.